GreatGigz Solutions v. CHRISTUS Health: Dismissed With Prejudice in Web Platform Patent Dispute

Introduction

In a decisive conclusion to nearly four years of litigation, the U.S. District Court for the Western District of Texas dismissed all patent infringement claims brought by GreatGigz Solutions, LLC against healthcare provider CHRISTUS Health — with prejudice — on September 19, 2025. The dismissal, entered on the plaintiff’s own motion following a prolonged stay, designated CHRISTUS Health as the prevailing party and entitled it to costs.

Case No. 6:21-cv-01310 centered on allegations that CHRISTUS Health’s patient-facing web platform, hosted at christushealth.org, infringed an unusually broad portfolio of 18 patents spanning web-based workforce management, data processing, and online scheduling technologies. The case’s resolution — without a merits ruling — carries important lessons for patent assertion entities, healthcare technology companies, and IP counsel navigating multi-patent litigation in one of the country’s most active patent venues.

Case Overview

The Parties

The Patents at Issue

Plaintiff asserted 19 U.S. patents, spanning web-based workforce management, data processing, and online scheduling technologies, including:

• • US9760864B2
• • US10096000B2
• • US7490086B2
• • US7148991B2
• • US6873964B1
• • US6662194B1
• • US6385620B1
• • US6363376B1
• • US6324538B1
• • US5978768A
• • US5832497A
• • US5164897A
• • US4625081A
• • US6381592B1
• • US6567784B2
• • US6332125B1
• • US6370510B1
• • US6383620B1
• • US20060190661A1

The Verdict & Legal Analysis

Outcome

The court granted GreatGigz’s own motion to lift the stay and dismiss all claims against CHRISTUS Health with prejudice. CHRISTUS Health was formally designated the prevailing party and entitled to costs. No damages were awarded to plaintiff; no final monetary figure was disclosed because the case never reached merits adjudication. A separate final judgment order was directed to follow.

Verdict Cause Analysis

The dismissal with prejudice — initiated by the plaintiff itself — is a significant strategic signal. Voluntary dismissal with prejudice operates as a final adjudication on the merits, permanently barring GreatGigz from re-asserting the same claims against CHRISTUS Health. Plaintiffs typically take this step only when continuing litigation is no longer viable or cost-effective.

The presence of a stay strongly implies that one or more of the 19 asserted patents faced serious validity challenges at the USPTO, likely through inter partes review (IPR) petitions filed by CHRISTUS Health or related parties. IPR proceedings have become a primary defense tool against PAE assertions, particularly where large patent portfolios are involved. If key patents were invalidated or significantly narrowed through IPR, the infringement theory targeting the Patient Portal would have collapsed accordingly.

The breadth of the asserted portfolio — 19 patents ranging from 1990s-era scheduling systems to 2017 web platform patents — is characteristic of PAE litigation tactics designed to maximize settlement pressure. CHRISTUS Health’s decision to retain a nine-attorney defense team across four law firms signals a commitment to a full-spectrum defense rather than early settlement.

Legal Significance

While this dismissal carries no precedential value as a merits ruling, it contributes to a documented pattern: healthcare system defendants with sufficient litigation resources can defeat broad PAE assertions by leveraging USPTO post-grant review proceedings. The case reinforces the strategic importance of IPR petitions as a first-line defense, particularly when faced with large, heterogeneous patent portfolios of varying vintage.

For patent claim construction purposes, no public claim construction order appears in the available record, meaning the case did not generate interpretive guidance on the specific web platform claims at issue.

Industry & Competitive Implications

This case sits at the intersection of two high-activity litigation domains: healthcare technology and web platform patent assertion. Healthcare systems have become frequent defendants in PAE litigation due to their adoption of digital patient engagement tools, often built on third-party platforms with complex IP provenance.

The dismissal outcome, combined with CHRISTUS Health’s prevailing party status and cost entitlement, sends a meaningful market signal: well-resourced healthcare defendants can and do defeat broad web-platform patent assertions. This may modestly deter similar filings against large health systems, though PAE litigation economics — particularly in plaintiff-friendly venues — mean assertion activity is unlikely to abate significantly.

The case also reflects broader licensing and assertion trends in workforce management and web platform patents, where portfolios assembled from legacy internet-era filings continue to generate litigation activity despite aging claim relevance. As USPTO IPR statistics consistently show invalidation rates above 60% for instituted petitions, defendants holding firm through post-grant proceedings increasingly achieve favorable outcomes.